In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Amol Chaubal Biography and Net Worth

CFO of Quanterix

MR. Amol Chaubal serves as Chief Financial Officer of the Company. Prior to joining us, Mr. Chaubal served as the CFO of Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019. Prior to his time at Smith & Nephew, he served as Corporate Vice President and Head of Finance for the Clinical Research Services business at Parexel from June 2015 to October 2017. Between May 2013 and May 2015, Mr. Chaubal served as CFO North America and Regional Chief Operating Officer at Brookfield Renewable Energy Group, which is part of Brookfield Asset Management. Prior to joining Brookfield, Mr. Chaubal was CFO North America at Novartis AG, where he spent 11 years in positions of increasing responsibility across Switzerland, Canada, and the United States. He has an M.B.A. (with distinction) from INSEAD (France). He began his career at Procter & Gamble Company after completing Masters degree in Chemical Engineering from the Indian Institute of Technology, Mumbai.

What is Amol Chaubal's net worth?: The estimated net worth of Amol Chaubal is at least $306,463.50 as of May 1st, 2020. Mr. Chaubal owns 26,082 shares of Quanterix stock worth more than $306,464 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Chaubal may own. Learn More about Amol Chaubal's net worth.
How do I contact Amol Chaubal?: The corporate mailing address for Mr. Chaubal and other Quanterix executives is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. Quanterix can also be reached via phone at (617) 301-9400 and via email at [email protected]. Learn More on Amol Chaubal's contact information.
Has Amol Chaubal been buying or selling shares of Quanterix?: Amol Chaubal has not been actively trading shares of Quanterix in the last ninety days. Most recently, Amol Chaubal sold 178 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $57.86, for a transaction totalling $10,299.08. Learn More on Amol Chaubal's trading history.
Who are Quanterix's active insiders?: Quanterix's insider roster includes Amol Chaubal (CFO), Marijn Dekkers (Director), David Duffy (SVP), John Fry (General Counsel), E Hrusovsky (CEO), Dawn Mattoon (VP), and Mark Roskey (SVP). Learn More on Quanterix's active insiders.
Are insiders buying or selling shares of Quanterix?: During the last year, Quanterix insiders bought shares 1 times. They purchased a total of 47,000 shares worth more than $624,630.00. During the last year, insiders at the sold shares 2 times. They sold a total of 2,500 shares worth more than $60,025.00. The most recent insider tranaction occured on August, 20th when Director David R Walt bought 47,000 shares worth more than $624,630.00. Insiders at Quanterix own 6.9% of the company. Learn More about insider trades at Quanterix.
Information on this page was last updated on 8/20/2024.

Amol Chaubal Insider Trading History at Quanterix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2021	Sell	178	$57.86	$10,299.08
4/1/2021	Sell	165	$62.52	$10,315.80
2/1/2021	Sell	133	$68.26	$9,078.58
1/5/2021	Sell	124	$44.13	$5,472.12
12/1/2020	Sell	115	$43.75	$5,031.25
11/2/2020	Sell	116	$36.97	$4,288.52
9/1/2020	Sell	120	$34.91	$4,189.20
8/3/2020	Sell	114	$32.26	$3,677.64
6/1/2020	Sell	118	$27.32	$3,223.76	26,082
5/1/2020	Sell	120	$25.44	$3,052.80	26,082
4/14/2020	Sell	1,463	$20.34	$29,757.42	26,082

Amol Chaubal Buying and Selling Activity at Quanterix

Quanterix Company Overview

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Today's Range

Now: $11.75

$11.58

$12.12

50 Day Range

MA: $12.86

$11.02

$15.49

2 Week Range

Now: $11.75

$10.50

$29.70

Volume

256,544 shs

Average Volume

476,778 shs

Market Capitalization

$450.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad